Director/PDMR Shareholding (2497E)
April 04 2011 - 9:33AM
UK Regulatory
TIDMHIK
RNS Number : 2497E
Hikma Pharmaceuticals Plc
04 April 2011
Annex DTR3
Notification of Transactions of Directors/Persons Discharging
Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital
letters
State whether the
notification
relates to (i) a
transaction
notified in
accordance with
DTR 3.1.2 R, (ii)
a disclosure made
in accordance
with LR 9.8.6R(1)
or (iii) a
disclosure made
in accordance
with section 793
of the Companies
Name of the Issuer: Act (2006): DTR
1. Hikma Pharmaceuticals PLC 2. 3.1.2 R
State whether
notification
relates to a
person connected
with a person
discharging
managerial
Name of person discharging responsibilities/
managerial director named in
responsibilities/director: 3 and identify
Samih Darwazah, Said the connected
Darwazah, Mazen Darwazah person: Yes:
3. and Ali Al-Husry 4. Darhold Limited
--------------------------- ---------------- ------------------
Description of
shares (including
Indicate whether the class),
notification is in respect debentures or
of a holding of the person derivatives or
referred to in 3 or 4 financial
above or in respect of a instruments
non-beneficial interest: relating to
Beneficial interest shares: Ordinary
5. Darhold Limited 6. Shares
--------------------------- ---------------- ------------------
State the nature
Name of registered of the
shareholders(s) and, if transaction: A
more than one, the number pledge over
of shares held by each of 5,000,000
them: Clearstream account Ordinary Shares
for and on behalf of in support of a
7. Europe Arab Bank plc 8. loan
--------------------------- ---------------- ------------------
Percentage of
issued class
acquired
(treasury shares
of that class
should not be
Number of shares, taken into
debentures or financial account when
instruments relating to calculating
9. shares acquired: None 10. percentage): N/A
--------------------------- ---------------- ------------------
Percentage of
issued class
disposed
(treasury shares
of that class
should not be
Number of shares, taken into
debentures or financial account when
instruments relating to calculating
11. shares disposed: None 12. percentage): N/A
--------------------------- ---------------- ------------------
Date and place of
Price per share or value transaction:
of transaction: London, 4 April
13. N/A 14. 2011
--------------------------- ---------------- ------------------
Total holding following
notification and total
percentage holding
following notification
(any treasury shares
should not be taken into Date issuer
account when calculating informed of
percentage): 57,183,028 - transaction: 4
15. 29.54 per cent. 16. April 2011
--------------------------- ---------------- ------------------
If a person discharging managerial responsibilities has been
granted options by the issuer complete the following boxes
------------------------------------------------------------------------------
Period during which
or date on which
17. Date of grant 18. exercisable
-------------------- ---------------- --------------------
Description of
Total amount paid shares or
(if any) for grant debentures involved
19. of the option 20. (class and number)
-------------------- ---------------- --------------------
Exercise price (if
fixed at time of Total number of
grant) or shares or
indication that debentures over
price is to be which options held
fixed at the time following
21. of exercise 22. notification
-------------------- ---------------- --------------------
Name of contact and
Any additional telephone number
23. information 24. for queries
-------------------- ---------------- --------------------
Name of authorised official or issuer responsible for making
notification
Henry Knowles, Company Secretary, Hikma Pharmaceuticals PLC
Date of notification: 4 April 2011
Notes:
This form is intended for use by an issuer to make a RIS
notification required by DTR 3.1.4
(1) An issuer making a notification in respect of a transaction
relating to the shares or debentures of the issuer should complete
boxes 1 to 16, 23 and 24.
(2) An issuer making a notification in respect of a derivative
relating the shares of the issuer should complete boxes 1 to 4, 6,
8, 13, 14, 16, 23 and 24.
(3) An issuer making a notification in respect of options
granted to a director/person discharging managerial
responsibilities should complete boxes 1 to 3 and 17 to 24.
(4) An issuer making a notification in respect of a financial
instrument relating to the shares of the issuer (other than a
debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16,
23 and 24.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBDGDSBDGBGBS
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
